{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "STLN",
  "name": "Starling Oncology, Inc.",
  "url": "https://frontierpicks.com/dossiers/STLN/",
  "json_url": "https://frontierpicks.com/dossiers/STLN.json",
  "status": "WATCHLIST",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a4",
    "n": 4
  },
  "current_thesis": "Starling Oncology’s oncology-risk contracts support a margin-expansion thesis that the next quarterly results must confirm. Third-quarter adjusted EBITDA within management’s $500,000–$1.5 million range and maintained full-year guidance would satisfy the immediate test; a weekly close below $5.25 invalidates the price structure.",
  "invalidation_trigger": "A weekly close below $5.25 breaks the consolidation reference identified on 2026-09-05; a reduction in FY2026 revenue guidance of $650–670 million or adjusted EBITDA guidance of $2–7 million, or a reported medical loss ratio above 90%, also breaks the operating thesis.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "managed-care-health-services"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Starling Oncology replaced The Oncology Institute name, and STLN replaced TOI effective 2026-08-04; older filings and historical records may use the former identifiers.",
    "Adjusted EBITDA is a non-GAAP measure. The 2026-08-06 release reported positive second-quarter adjusted EBITDA alongside a $9.8 million net loss."
  ],
  "body_markdown": "## Current Thesis\n\nStarling Oncology’s oncology-risk contracts support a margin-expansion thesis that the next quarterly results must confirm through positive adjusted earnings and maintained guidance. The 2026-08-06 earnings release reported second-quarter revenue of $161.3 million, up 34.6% year over year, and gross profit of $27.2 million, up 55.2%. Adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) reached $229,000, while the company reported a $9.8 million net loss. These are measured results; sustained profitability remains unproven.\n\nThe substantive update since the 2026-09-05 note is the completed conference appearance. On 2026-09-08, Chief Financial Officer Rob Carter described a 2027 capitated-revenue outlook of $300 million against $150 million for 2026, linking it to contracted expansion. Capitation means receiving agreed payments while assuming responsibility for covered care costs. That outlook is management’s forecast, not recognized revenue. [Wells Fargo conference transcript](https://stockanalysis.com/stocks/stln/transcripts/738867-wells-fargo-21st-annual-healthcare-conference/)\n\nThe narrative is maturing — the 2026-09-08 conference extended the contract-growth argument established by the 2026-08-06 results, while the 2026-09-11 adjusted close remained below the supplied annual high. This is a lifecycle inference, not evidence of declining institutional participation. The case succeeds at the next quarterly test if reported adjusted EBITDA meets management’s third-quarter range and full-year guidance remains intact; a weekly close below $5.25 invalidates the price structure first.\n\n## Bull Case\n\n- **Gross profit outgrew reported revenue.** The 2026-08-06 release reported second-quarter gross-profit growth of 55.2% against revenue growth of 34.6%. The aggregate result supports margin improvement, although it does not establish which segment caused it.\n- **The next earnings hurdle is explicit.** On 2026-08-06, management guided third-quarter 2026 adjusted EBITDA to $500,000–$1.5 million and full-year revenue to $650–670 million. Results below the quarterly range would fail the immediate confirmation test.\n- **Contract expansion underpins management’s outlook.** At the 2026-09-08 conference, Carter tied the 2027 capitated-revenue forecast to Florida and California expansion and Nevada and Oregon contracts. Delayed implementation or a reduction in that forecast would contradict the expansion argument. [Conference transcript](https://stockanalysis.com/stocks/stln/transcripts/738867-wells-fargo-21st-annual-healthcare-conference/)\n\n## Bear Case\n\n- **Adjusted profitability remains narrowly established.** The 2026-08-06 release paired second-quarter adjusted EBITDA of $229,000 with a $9.8 million net loss. The sample is too small to support a claim of durable profitability.\n- **Medical costs govern contract economics.** Management’s 2026-08-06 outlook specified a medical loss ratio of 80–90%, measuring medical costs relative to the associated revenue. A reported ratio above 90% would breach that operating assumption.\n- **Revenue composition limits the inference.** Specialty Pharmacy supplied $98.6 million of second-quarter 2026 revenue, according to the 2026-08-06 release. Company-wide gross-profit growth alone cannot establish improved profitability within the capitated business; the next segment disclosures must resolve that attribution.\n\n## Setup & Price Structure\n\nThe supplied adjusted daily series records a $6.17 close on 2026-09-11, 7.4% below its $6.66 annual high, with a three-month price increase of 16.2%. The 14-period relative strength index (RSI) measured 43.6 on that date. The shares therefore remained below the annual high despite the positive three-month change; these observations do not establish expanding participation.\n\nThe $5.25 consolidation reference identified in the 2026-09-05 published note remains the thesis-break level. No moving-average value or trading-volume series accompanies the 2026-09-11 observations, so neither support from a rising average nor volume confirmation can be claimed.\n\nThe company’s filing index lists a Form 144 dated 2026-08-21 and a Form 4 dated 2026-08-24. Those are observable filing events; the index alone does not establish completed selling, its magnitude, or issuance into strength. Retail sentiment and short-interest measurements are unavailable in the evidence reviewed, preventing a crowding conclusion. [Company filing index](https://toimanagement.gcs-web.com/financial-information/sec-filings)\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-09-13 through 2026-10-13:** No company-confirmed catalyst within this window was identified on the investor-relations calendar reviewed on 2026-09-13. Its latest listed event was the completed 2026-09-08 Wells Fargo presentation, which is no longer an upcoming catalyst. [Company calendar](https://investors.starlingoncology.com/)\n- **~2026-11-05, estimated:** Third-quarter 2026 results remain the decisive operating test. This date is the estimate used in the 2026-09-05 published note, not a company-confirmed appointment. The report tests the $500,000–$1.5 million adjusted EBITDA range and $650–670 million full-year revenue guidance issued on 2026-08-06.\n\n## What Would Change Our Mind\n\nLoss of the August consolidation structure would end the technical case: a weekly close below $5.25 breaches the reference identified on 2026-09-05. The operating argument also breaks if management reduces its 2026 revenue guidance of $650–670 million or adjusted EBITDA guidance of $2–7 million, or reports a medical loss ratio above the 90% ceiling specified on 2026-08-06.\n\nA third-quarter report within the guided adjusted EBITDA range, with full-year guidance maintained, would satisfy the immediate confirmation test. It would add evidence of persistence without establishing a durable trend. The current evidence supports medium conviction because the measured improvement rests on the 2026-08-06 quarterly release, while the subsequent conference supplied management expectations rather than another reported quarter.\n\n## Correlation Notes\n\nThis remains a single-name operating thesis. No paired return series is available as of 2026-09-11 to support a measured correlation with managed-care equities, biotechnology stocks, or commodities.\n\nThe relevant economic connection is to payer contracts and medical utilization: management’s 2026-08-06 outlook combined approximately $150 million of annual capitated revenue with an 80–90% medical loss ratio. Sensitivity to care costs is an inference from that contract model; it is not evidence that STLN follows a healthcare index. A reported ratio above the guided ceiling would challenge the company-specific margin thesis regardless of the sector’s price direction.",
  "first_seen": "2026-09-04",
  "last_analyzed": "2026-09-13T12:04:37+00:00",
  "last_synthesized": "2026-09-13",
  "last_update_source": "watchlist_research",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}